Cue Biopharma licenses CUE-100 series to ImmunoScape; receives $15M cash and 40% equity

Cue Biopharma, Inc.

Collaboration with ImmunoScape to develop 'Seed-and-Boost' TCR-T cell therapy for solid tumors using CUE-100 series.
Cue Biopharma receives $15M upfront ($10M in Q4 2025, $5M in Nov 2026) and 40% equity stake in ImmunoScape.
Cue Biopharma eligible for high-single-digit royalties on net sales of any products developed.
IND-enabling studies on track for 2027 submission; preclinical data shown in pancreatic and ovarian cancer models.
Cue Biopharma to focus on autoimmune disease programs while oncology development advances with ImmunoScape.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.